Osteosarcoma primarily affects long bones in teenagers and young adults, requiring early diagnosis for effective treatment. Treatment strategies vary by stage, with surgery and chemotherapy as primary ...

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...

Researchers have been able to identify at least three distinct subtypes of a rare type of bone cancer for the first time, which could transform clinical trials and patient care. While genetic ...

Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer "This Break Through Cancer project brings a ...

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its ...

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, ...

(RTTNews) - OS Therapies, Inc. (OSTX), a clinical-stage biopharma company specializing in immunotherapies and antibody-drug conjugates, has launched a new subsidiary, OS Animal Health, Inc., to lead ...